Novartis says its chimeric antigen receptors (CAR-T) candidate is on track for filing in 2017, which could make it the first of the novel drugs to hit the market.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.